A Phase I/II Evaluation of Stavudine (d4T) in Children With Human Immunodeficiency Virus Infection
Mark W. Kline(Tulane University), William T. Shearer(Baylor College of Medicine), Diane F. Loewen(Baylor College of Medicine), Sanjeev Kaul(AstraZeneca (United States)), I. Celine Hanson(Baylor College of Medicine), Jonathan C. Goldsmith(National Heart Lung and Blood Institute), Victoria L. Rutkiewicz(Baylor College of Medicine), Lisa M. Dunkle(Merck & Co., Inc., Rahway, NJ, USA (United States)), Joseph A. Church(University of Southern California), Howard M. Rosenblatt(Baylor College of Medicine), Lin Woods(Baylor College of Medicine), Anne Cross(Bristol-Myers Squibb (United States)), Alice T. Harris(Baylor College of Medicine), Marianne E. Federici(Baylor College of Medicine), Mary E. Schultze(Baylor College of Medicine)
Cited by 79
Related Papers
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Management of Sickle Cell Disease
|JAMA|2014|1.6k
Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1–Infected Women and Prevention of Perinatal HIV-1 Transmission
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2002|896
Lymphocyte subsets in healthy children from birth through 18 years of age
|Journal of Allergy and Clinical Immunology|2003|828
Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1–Infected Women and Prevention of Perinatal HIV-1 Transmission
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2002|697